Evidence map›Paper›PMID 30239935›Full record

ReviewSleep2019

Histamine: neural circuits and new medications.

Thomas E Scammell, Alexander C Jackson, Nicholas P Franks, William Wisden, Yves Dauvilliers

Open access · hybridAbstract readReview
In one paragraph

Review in Sleep, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Development and Preclinical Characterization of [Journal of medicinal chemistry · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Thomas E ScammellDepartment of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Alexander C JacksonDepartment of Physiology and Neurobiology, University of Connecticut, Storrs, CT.
Nicholas P FranksDepartment of Life Sciences and UK Dementia Research Institute, Imperial College London, UK.
William WisdenDepartment of Life Sciences and UK Dementia Research Institute, Imperial College London, UK.
Yves DauvilliersCentre National de Référence Narcolepsie Hypersomnies, Unité des Troubles du Sommeil, Service de Neurologie, Hôpital Gui-de-Chauliac, Université Montpellier, INSERM, Montpellier, France.
Imperial College London · GBHarvard University · USUniversité de Montpellier · FRUniversity of Connecticut · US

Funding

Wakefulness and Forebrain Activation by Orexin NeuronsP01HL095491 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MCCARLEY, ROBERT W · 2010 to 2019
$25.1M
Inhibitory Cell Types and Circuits in the Lateral HypothalamusR01MH112739 · NIMH · UNIVERSITY OF CONNECTICUT STORRS · PI Alexander Choi Jackson · 2017 to 2026
$5.1M
Mechanisms of CataplexyR01NS106032 · NINDS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCAMMELL, THOMAS E · 2018 to 2021
$1.6M
Synaptic Mechanisms of Hypothalamic Control of Vigilance and Cognitive FunctionR00MH097792 · NIMH · UNIVERSITY OF CONNECTICUT STORRS · PI JACKSON, ALEXANDER CHOI · 2013 to 2015
$734k
Synaptic Mechanisms of Hypothalamic Control of Vigilance and Cognitive FunctionK99MH097792 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JACKSON, ALEXANDER CHOI · 2012 to 2013
$99k
Medical Research CouncilNHLBI NIH HHS P01 HL095491NIMH NIH HHS K99 MH097792NIMH NIH HHS R00 MH097792NIMH NIH HHS R01 MH112739NINDS NIH HHS R01 NS106032Wellcome Trust 107839/Z/15/ZWellcome Trust 107841Wellcome Trust 107841/Z/15/Z
6 · The paper itself

Abstract

Histamine was first identified in the brain about 50 years ago, but only in the last few years have researchers gained an understanding of how it regulates sleep/wake behavior. We provide a translational overview of the histamine system, from basic research to new clinical trials demonstrating the usefulness of drugs that enhance histamine signaling. The tuberomammillary nucleus is the sole neuronal source of histamine in the brain, and like many of the arousal systems, histamine neurons diffusely innervate the cortex, thalamus, and other wake-promoting brain regions. Histamine has generally excitatory effects on target neurons, but paradoxically, histamine neurons may also release the inhibitory neurotransmitter GABA. New research demonstrates that activity in histamine neurons is essential for normal wakefulness, especially at specific circadian phases, and reducing activity in these neurons can produce sedation. The number of histamine neurons is increased in narcolepsy, but whether this affects brain levels of histamine is controversial. Of clinical importance, new compounds are becoming available that enhance histamine signaling, and clinical trials show that these medications reduce sleepiness and cataplexy in narcolepsy.

Indexed as

AnimalsCataplexygamma-Aminobutyric AcidHistamineHumansHypothalamic Area, LateralNarcolepsyNeuronsSignal TransductionWakefulnessgamma-Aminobutyric AcidHistamine

Identifiers

PMID30239935
PMCPMC6335869
OpenAlexW2891266274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.